T1	intervention 10 19	tamoxifen
T2	condition 23 51	venous thromboembolic events
T3	No-of-participants 490 494	5408
T4	eligibility 495 516	hysterectomized women
T5	control 559 566	placebo
T6	duration 571 578	5 years
T7	outcome-Measure 458 474	incidence of VTE
T8	control-value 591 593	28
T9	outcome 594 598	VTEs
T10	intervention-value 614 616	44
T11	outcome 863 887	risk of VTE on tamoxifen
T12	control-value 1178 1179	1
T13	intervention-value 1203 1205	13
T14	outcome 1227 1240	developed VTE
